Form 4: Recursion Pharma CFO Sells Shares for Tax Obligations

Recursion Pharmaceuticals' CFO, Ben R. Taylor, disposed of 7,057 shares of Class A Common Stock to cover tax obligations related to restricted stock unit settlement.

Summary

• Ben R. Taylor, Chief Financial Officer of RECURSION PHARMACEUTICALS, INC. (RXRX), reported a transaction on December 15, 2025.
• The transaction involved the disposition of 7,057 shares of Class A Common Stock.
• These shares were withheld by the Issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
• The shares were disposed of at a price of $4.33 per share.
• Following this transaction, Mr. Taylor beneficially owns 782,933 shares of Class A Common Stock directly.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary disposition of shares for tax withholding purposes upon RSU vesting. It is neutral in terms of indicating positive or negative sentiment towards the company's future prospects.

Positives

• The transaction is a non-discretionary disposition for tax purposes, not indicative of a change in management's outlook on the company's future.
• Ben R. Taylor retains a significant beneficial ownership of 782,933 shares of Class A Common Stock, maintaining substantial alignment with shareholder interests.

Negatives

• A reduction in direct beneficial ownership by an officer, even for tax purposes, technically decreases insider holdings.

Future Outlook

This filing, a Form 4, does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This type of insider transaction, involving the disposition of shares to cover tax obligations upon the vesting of restricted stock units, is a common and routine event for executives in publicly traded companies across all industries. It does not typically reflect a change in the company's operational performance or strategic position within the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary transaction for tax purposes and the CFO retains significant ownership.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary disposition of shares by the CFO to cover tax obligations related to restricted stock unit vesting. Such transactions are common and do not typically signal a change in the company's fundamental outlook or management's confidence. Therefore, it does not provide new information that would warrant a change in an existing investment thesis, leading to a 'hold' recommendation.

Keywords

RXRX, Recursion Pharmaceuticals, Form 4, insider transaction, stock disposition, CFO, Ben R Taylor, tax withholding, restricted stock units